BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26317919)

  • 1. Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
    Pelosi G; Fabbri A; Papotti M; Rossi G; Cavazza A; Righi L; Tamborini E; Perrone F; Settanni G; Busico A; Testi MA; Maisonneuve P; De Braud F; Garassino M; Valeri B; Sonzogni A; Pastorino U
    J Thorac Oncol; 2015 Nov; 10(11):1560-9. PubMed ID: 26317919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
    Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
    Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach.
    Pelosi G; Fabbri A; Bianchi F; Maisonneuve P; Rossi G; Barbareschi M; Graziano P; Cavazza A; Rekhtman N; Pastorino U; Scanagatta P; Papotti M
    J Thorac Oncol; 2012 Feb; 7(2):281-90. PubMed ID: 22071786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma.
    Hwang DH; Szeto DP; Perry AS; Bruce JL; Sholl LM
    Arch Pathol Lab Med; 2014 May; 138(5):626-35. PubMed ID: 23738762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53, NOTCH2, and STK11 Mutations in a Rare Tumor of non-Small Cell Lung Carcinoma with Diffuse Coexpression of TTF1 and p40 in the Same Tumor Cells.
    Guo X; Dong L; Liu H; Chen X
    Int J Surg Pathol; 2023 Sep; 31(6):1041-1047. PubMed ID: 36253711
    [No Abstract]   [Full Text] [Related]  

  • 8. Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma.
    Xu JB; Bao Y; Liu X; Liu Y; Huang S; Wang JC
    Lung Cancer; 2007 Oct; 58(1):36-43. PubMed ID: 17566598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal.
    Pelosi G; Barbareschi M; Cavazza A; Graziano P; Rossi G; Papotti M
    Lung Cancer; 2015 Mar; 87(3):226-31. PubMed ID: 25620799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization.
    Pelosi G; Rossi G; Cavazza A; Righi L; Maisonneuve P; Barbareschi M; Graziano P; Pastorino U; Garassino M; de Braud F; Papotti M
    Int J Surg Pathol; 2013 Jun; 21(3):229-39. PubMed ID: 23486764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
    Pelosi G; Haspinger ER; Bimbatti M; Leone G; Paolini B; Fabbri A; Tamborini E; Perrone F; Testi A; Garassino M; Maisonneuve P; de Braud F; Pilotti S; Pastorino U
    Int J Surg Pathol; 2014 Apr; 22(2):136-48. PubMed ID: 24326823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma].
    Hou LK; Zhang LP; Zhang W; Huang Y; Wu W; Dong ZW; Wu CY
    Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):298-302. PubMed ID: 28468033
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
    Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
    Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.
    Rodriguez EF; VandenBussche CJ; Chowsilpa S; Maleki Z
    Cancer Cytopathol; 2018 Oct; 126(10):853-859. PubMed ID: 30199148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Pulmonary Mucoepidermoid Carcinoma: Histopathological and Moleculargenetic Studies of 26 Cases.
    Huo Z; Wu H; Li J; Li S; Wu S; Liu Y; Luo Y; Cao J; Zeng X; Liang Z
    PLoS One; 2015; 10(11):e0143169. PubMed ID: 26575266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology.
    Rossi G; Mengoli MC; Cavazza A; Nicoli D; Barbareschi M; Cantaloni C; Papotti M; Tironi A; Graziano P; Paci M; Stefani A; Migaldi M; Sartori G; Pelosi G
    Virchows Arch; 2014 Jan; 464(1):61-8. PubMed ID: 24221342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1
    Agaimy A; Fuchs F; Moskalev EA; Sirbu H; Hartmann A; Haller F
    Virchows Arch; 2017 Nov; 471(5):599-609. PubMed ID: 28555282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer.
    Karlsson A; Brunnström H; Lindquist KE; Jirström K; Jönsson M; Rosengren F; Reuterswärd C; Cirenajwis H; Borg Å; Jönsson P; Planck M; Jönsson G; Staaf J
    Oncotarget; 2015 Sep; 6(26):22028-37. PubMed ID: 26124082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.
    Rekhtman N; Tafe LJ; Chaft JE; Wang L; Arcila ME; Colanta A; Moreira AL; Zakowski MF; Travis WD; Sima CS; Kris MG; Ladanyi M
    Mod Pathol; 2013 Apr; 26(4):511-22. PubMed ID: 23196793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies.
    Forest F; Yvorel V; Karpathiou G; Stachowicz ML; Vergnon JM; Fournel P; Tiffet O; Trombert B; Péoc'h M
    Hum Pathol; 2016 Mar; 49():99-106. PubMed ID: 26826416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.